AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company

• Court: Court of Chancery of Delaware
• Decided: September 17, 2021
• Docket: CA No. 2020-0953-SG
• Status: Published

Opinion

COURT OF CHANCERY OF THE SAM GLASSCOCK III VICE CHANCELLOR STATE OF DELAWARE COURT OF CHANCERY COURTHOUSE 34 THE CIRCLE GEORGETOWN, DELAWARE 19947

September 17, 2021

A. Thompson Bayliss, Esquire Kevin R. Shannon, Esquire Joseph A. Sparco, Esquire Christopher N. Kelly, Esquire ABRAMS & BAYLISS LLP Daniel M. Rusk, IV, Esquire 20 Montchanin Rd., Suite 200 POTTER ANDERSON & CORROON LLP Wilmington, DE 19807 1313 N. Market St. Hercules Plaza, 6th Floor Wilmington, DE 19801

RE: AbbVie Endocrine Inc. v. Takeda Pharmaceutical Company Limited, C.A. No. 2020-0953-SG

Dear Counsel:

I have considered the Defendant’s Motion to Supplement the Trial Record,

the Plaintiff’s Motion to Supplement the Trial Record (together, the “Cross-

Motions”) and the Plaintiff’s Limited Opposition to Defendant’s Motion to

Supplement the Trial Record.

The Cross-Motions are hereby granted, with the exception of Exhibit 1 to the

Defendant’s Motion (“Exhibit 1”), which is a gloss on disputed facts that would

require supplemental discovery in order for the Plaintiff to address. In any event,

Exhibit 1 is not dispositive of my decision. To the extent the foregoing requires an order to take effect, it is SO

ORDERED.

Sincerely,

/s/ Sam Glasscock III Vice Chancellor

cc: All counsel of record (by File & ServeXpress)